Coverage
-
October 20, 2017
Gilead Sciences won its bid to transfer a patent infringement suit filed by the University of Minnesota over the company's blockbuster hepatitis C drugs to California on Friday when a Minnesota federal judge invoked a recent Federal Circuit ruling that says such actions can be filed only where a defendant has a long-standing physical location.
1 other articles on this case.
View all »